Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib in Relapsed or Refractory Hairy Cell Leukemia
NCT01711632Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2012
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib in hairy cell leukemia (HCL), sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2012; status: completed.
02
Drugs
vemurafenib
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT01711632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01711632.